Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 3 | 1 |
List of Figures | 3 | 2 |
Executive Summary | 5 | 1 |
Biologics and mAbs Growing in Prominence in Asthma Treatment | 5 | 1 |
Market Landscape to Grow in Diversity over Coming Years | 5 | 1 |
Cytokine and Kinase Targeted Small Molecules and mAbs Dominate First-in-Class Innovation | 5 | 1 |
Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products | 5 | 1 |
The Case for Innovation in the Asthma Market | 6 | 4 |
Growing Number of Opportunities for Biologic Products | 7 | 1 |
Diversification of Molecular Targets | 7 | 1 |
Innovative First-in-Class Product Developments Remain Attractive | 7 | 1 |
Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications | 8 | 1 |
Sustained Innovation | 8 | 1 |
GBI Research Report Guidance | 9 | 1 |
Clinical and Commercial Landscape | 10 | 13 |
Disease Overview | 10 | 1 |
Epidemiology | 10 | 1 |
Etiology | 11 | 1 |
Pathophysiology | 11 | 1 |
Disease Symptoms | 12 | 1 |
Diagnosis | 12 | 1 |
Disease Prgnosis | 13 | 1 |
Assessment of Disease Severity | 13 | 2 |
Treatment | 15 | 1 |
Quick-Relief Medication | 15 | 1 |
ICSs for the Maintenance Treatment of Asthma | 16 | 1 |
ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma | 16 | 1 |
Add-on Therapies to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma | 17 | 1 |
Treatment Algorithm | 18 | 3 |
Overview of Marketed Products | 21 | 1 |
Current Unmet Need in the Asthma Market | 22 | 1 |
Assessment of Pipeline Product Innovation | 23 | 10 |
Asthma Pipeline by Molecule Type, Stage of Development and Molecular Target | 23 | 6 |
Comparative Distribution of Programs between the Asthma Market and Pipeline by Molecular Target | 29 | 1 |
First-in-Class Pipeline Programs Targeting Novel Molecular Targets | 29 | 4 |
Signaling Network and Innovation Alignment | 33 | 3 |
Complexity of Signaling Networks in Asthma | 33 | 1 |
First-in-Class Matrix Assessment | 33 | 3 |
First-in-Class Target Evaluation | 36 | 10 |
Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1 | 36 | 1 |
Overview of Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1 | 37 | 1 |
Pipeline Programs Targeting CXC Chemokine Receptors | 37 | 1 |
Overview of Pipeline Programs Targeting CXC Chemokine Receptors | 38 | 1 |
Pipeline Programs Targeting Spleen Tyrosine Kinase | 38 | 1 |
Overview of Pipeline Programs Targeting Spleen Tyrosine Kinase | 39 | 1 |
Pipeline Programs Targeting Compliment Component 5a Receptor 1 | 40 | 1 |
Overview of Pipeline Programs Targeting Compliment Component 5a Receptor 1 | 40 | 1 |
Pipeline Programs Targeting Interleukin-33 | 41 | 1 |
Overview of Pipeline Programs Targeting Interleukin-33 | 41 | 1 |
Pipeline Programs Targeting CC Chemokine Receptor Type 3 | 42 | 1 |
Overview of Pipeline Programs Targeting CC Chemokine Receptor Type 3 | 42 | 1 |
Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d | 43 | 1 |
Overview of Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d | 44 | 1 |
Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha | 44 | 1 |
Overview of Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha | 45 | 1 |
Conclusion | 45 | 1 |
Deals and Strategic Consolidations | 46 | 11 |
Industry-Wide First-in-Class Deals | 46 | 1 |
Asthma Deals Landscape | 47 | 1 |
Licensing Deals | 48 | 2 |
Molecule Type | 50 | 1 |
Molecular Target | 50 | 2 |
Co-development Deals | 52 | 1 |
Molecule Type | 53 | 1 |
Molecular Target | 53 | 2 |
Pipeline Products without Prior Licensing or Co-Development Deal Involvement | 55 | 2 |
Appendix | 57 | 5 |
References | 57 | 2 |
Abbreviations | 59 | 1 |
Primary Research | 60 | 1 |
Contact Us | 61 | 1 |
Disclaimer | 61 | 1 |